Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Rosiglitazone in Type 2 Diabetes
NCT00523913Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rosiglitazone in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Nov 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00523913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523913.